新鲜与标准库存红细胞输注对危重患儿多器官功能障碍综合征的影响:一项随机临床试验
这项国际多中心盲法随机临床试验纳入1538例危重患儿,比较新鲜红细胞(储存≤7天)与标准库存红细胞输注对28天内新发或进展性多器官功能障碍综合征的影响。
要点
- 危重患儿输注新鲜红细胞未降低新发或进展性MODS发生率。
- 新鲜组与标准组MODS发生率分别为20.2%和18.2%,差异无统计学意义。
- 两组脓毒症、ARDS发生率及ICU死亡率均无显著差异。
核心结论
- 在危重患儿中,与标准库存红细胞相比,输注新鲜红细胞并未降低新发或进展性多器官功能障碍综合征(包括死亡)的发生率。
主要发现
- 脓毒症发生率:新鲜组25.8%(160/619),标准组25.3%(154/608)。
- 急性呼吸窘迫综合征发生率:新鲜组6.6%(41/619),标准组4.8%(29/608)。
临床怎么用
- 危重患儿红细胞输注时无需刻意追求新鲜血,使用标准库存红细胞即可。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The clinical consequences of red blood cell storage age for critically ill pediatric patients have not been examined in a large, randomized clinical trial. OBJECTIVE: To determine if the transfusion of fresh red blood cells (stored ≤7 days) reduced new or progressive multiple organ dysfunction syndrome compared with the use of standard-issue red blood cells in critically ill children. DESIGN, SETTING, AND PARTICIPANTS: The Age of Transfused Blood in Critically-Ill Children trial was an international, multicenter, blinded, randomized clinical trial, performed between February 2014 and November 2018 in 50 tertiary care centers. Pediatric patients between the ages of 3 days and 16 years were eligible if the first red blood cell transfusion was administered within 7 days of intensive care unit admission. A total of 15 568 patients were screened, and 13 308 were excluded. INTERVENTIONS: Patients were randomized to receive either fresh or standard-issue red blood cells. A total of 1538 patients were randomized with 768 patients in the fresh red blood cell group and 770 in the standard-issue group. MAIN OUTCOMES AND MEASURES: The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured for 28 days or to discharge or death. RESULTS: Among 1538 patients who were randomized, 1461 patients (95%) were included in the primary analysis (median age, 1.8 years; 47.3% girls), in which there were 728 patients randomized to the fresh red blood cell group and 733 to the standard-issue group. The median storage duration was 5 days (interquartile range [IQR], 4-6 days) in the fresh group vs 18 days (IQR, 12-25 days) in the standard-issue group (P < .001). There were no significant differences in new or progressive multiple organ dysfunction syndrome between fresh (147 of 728 [20.2%]) and standard-issue red blood cell groups (133 of 732 [18.2%]), with an unadjusted absolute risk difference of 2.0% (95% CI, -2.0% to 6.1%; P = .33). The prevalence of sepsis was 25.8% (160 of 619) in the fresh group and 25.3% (154 of 608) in the standard-issue group. The prevalence of acute respiratory distress syndrome was 6.6% (41 of 619) in the fresh group and 4.8% (29 of 608) in the standard-issue group. Intensive care unit mortality was 4.5% (33 of 728) in the fresh group vs 3.5 % (26 of 732) in the standard-issue group (P = .34). CONCLUSIONS AND RELEVANCE: Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01977547.
引用
- Spinella PC, Tucci M, Fergusson DA, et al. Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial. JAMA. 2019. PMID: 31821429. doi:10.1001/jama.2019.17478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。